Advanced search
Publication Cover
Scandinavian Journal of Urology Volume 54, 2020 - Issue 2
Journal homepage
105
Views
1
CrossRef citations to date
0
Altmetric
Articles

Feasibility and efficacy of sequential systemic therapy for metastatic castration-resistant prostate cancer in a rural health care setting

Carsten NiederDepartment of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway; ;Department of Clinical Medicine, Faculty of Health Sciences, UiT – The Arctic University of Norway, Tromsø, NorwayCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-1592-2908
ORCID Icon,
Astrid DalhaugDepartment of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway; ;Department of Clinical Medicine, Faculty of Health Sciences, UiT – The Arctic University of Norway, Tromsø, Norway
&
Ellinor HauklandDepartment of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway; ;Department of Clinical Medicine, Faculty of Health Sciences, UiT – The Arctic University of Norway, Tromsø, NorwayORCID Iconhttp://orcid.org/0000-0002-5697-2218
ORCID Icon
Pages 110-114 | Received 12 Dec 2019, Accepted 12 Feb 2020, Published online: 24 Feb 2020

References

  • Nuhn P, De Bono JS, Fizazi K, et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol. 2019;75:88–99.
  • Norum J, Nieder C. Treatments for metastatic prostate cancer (mPC): a review of costing evidence. Pharmacoeconomics. 2017;35:1223–1236.
  • Nieder C, Haukland E, Mannsåker B, et al. Impact of intense systemic therapy and improved survival on the use of palliative radiotherapy in patients with bone metastases from prostate cancer. Oncol Lett. 2016;12:2930–2935.
  • Delanoy N, Hardy-Bessard AC, Efstathiou E, et al. Sequencing of taxanes and new androgen-targeted therapies in metastatic castration-resistant prostate cancer: results of the international multicentre retrospective CATS database. Eur Urol Oncol. 2018;1:467–475.
  • Akaza H, Procopio G, Pripatnanont C, et al. Metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy: treatment patterns from the PROXIMA prospective registry. J Glob Oncol. 2018;4:1–12.
  • Miyake H, Matsushita Y, Tamura K, et al. Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide. Med Oncol. 2017;34:200.
  • Alghazali M, Löfgren A, Jørgensen L, et al. A registry-based study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Scand J Urol. 2019;53:312–318.
  • Nieder C, Dalhaug A, Haukland E, et al. Contemporary radiooncological management of bone metastases from breast cancer: factors associated with prescription of different fractionation regimens (short or long course) in a rural part of North Norway with long travel distance. Int J Circumpolar Health. 2017;76:1270080.
  • Nieder C, Norum J, Spanne O, et al. Does distance to treatment centre influence the rate of palliative radiotherapy in adult cancer patients? Anticancer Res. 2009;29:2641–2644.
  • Nieder C, Haukland E, Mannsåker B, et al. Initiation of systemic therapy during the last 30 days of life in patients with metastatic castration-resistant prostate cancer. Anticancer Res. 2019;39:335–340.
  • de Wit R, de Bono J, Sternberg CN, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381:2506–2518.
  • Zarrabi K, Paroya A, Wu S. Emerging therapeutic agents for genitourinary cancers. J Hematol Oncol. 2019;12:89.
  • Lorente D, Fizazi K, Sweeney C, et al. Optimal treatment sequence for metastatic castration-resistant prostate cancer. Eur Urol Focus. 2016;2:488–498.
  • Nieder C, Dalhaug A, Haukland E, et al. Management of patients with metastatic prostate cancer (mPC) in a rural part of North Norway with a scattered population: does living near the department of oncology translate into a different pattern of care and survival? Int J Circumpolar Health. 2019;78:1620086.
  • Baade PD, Yu XQ, Smith DP, et al. Geographic disparities in prostate cancer outcomes–review of international patterns. Asian Pac J Cancer Prev. 2015;16:1259–1275.
  • Charlton M, Schlichting J, Chioreso C, et al. Challenges of rural cancer care in the United States. Oncology (Williston Park). 2015;29:633–640.
  • Young TK, Kelly JJ, Friborg J, et al. Cancer among circumpolar populations: an emerging public health concern. Int J Circumpolar Health. 2016;75:29787.
  • Sade JP, Báez CAV, Greco M, et al. Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective. Med Oncol. 2018;35:56.
  • Oh WK, Miao R, Vekeman F, et al. Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting. Med Oncol. 2017;34:160.
  • Crombag MBS, de Vries Schultink AHM, van Doremalen JGC, et al. Age-associated hematological toxicity in patients with metastatic castration-resistant prostate cancer treated with docetaxel in clinical practice. Drugs Aging. 2019;36:379–385.
  • Droz JP, Albrand G, Gillessen S, et al. Management of prostate cancer in elderly patients: recommendations of a task force of the International Society of Geriatric Oncology. Eur Urol. 2017;72:521–531.
  • Caffo O, Maines F, Rizzo M, et al. Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions. Clin Interv Aging. 2016;12:19–28.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.